Juillerat-Jeanneret,Dyson, and co-workers attached modified phenoxazine- and anthracene-basedMDR modulator ligands to a ruthenium(II) organometallic scaffold (Scheme 1A).4 These compounds were found to be MDR-reverting agents ableto inhibit P-gp at 80 μM in the lung cancer A549 cell line,showing similar efficiency as the known P-gp and MRP1 inhibitor verapamil.However, a decrease in in vitro selectivity was observedas for many other ABC transporter inhibitors. The gene discussed is PGP; the disease is lung cancer.